CellCodex combines human cell engineering, experimental perturbation and AI modelling to investigate disease biology. Its Max-Diff approach aims to connect biological changes with their causes.
Correlative snapshots describe what changes, but do not necessarily explain why. CellCodex’s approach brings disease-relevant human cell states and designed perturbations into the experimental loop.
Why causal data?Model the biological question in relevant human cell states.
Investigate responses to genetic and compound changes.
Connect single-cell measurements with imaging.
Max-Diff is a company-described research and data platform. Human cell engineering, perturbation, measurement and modelling inform one another in a continuous experimental loop.
Programme human stem cells into target cell types and develop aged, disease-relevant states.
Research architecture, not clinical validation.
Cell purity, maturity benchmarks and reproducibility datasets are not published in the reviewed material.
Research architecture, not clinical validation.Programme human stem cells into target cell types and develop aged, disease-relevant states.
Cell purity, maturity benchmarks and reproducibility datasets are not published in the reviewed material.
Investigate genetic and compound perturbations at genome scale, including mature neuronal models.
Library coverage, experimental capacity and complete screening data are not specified.
Single-cell multi-omics and live/high-content imaging produce multimodal measurements.
Commercial deliverable specifications, data size and quality-control thresholds are not established.
AI models use measurements to predict perturbation response and inform subsequent experiments.
Predictive accuracy, prospective validation and software access are not established.
The company schematic connects new wet-lab measurements to model development and separates independent held-out datasets for checking predictions. This architecture is not a published predictive-performance result.
The published programme examples explore neurodegeneration and liver toxicity. Neither is presented here as an approved therapy or a clinically validated product.
CellCodex reports genome-wide screens in human dopamine neurons that indicated a novel pathway now being investigated.
CellCodex reports genome-wide screens in human dopamine neurons that indicated a novel pathway now being investigated. The reviewed material does not identify the pathway or establish a named clinical candidate, clinical phase or patient efficacy.
A research programme investigating human hepatocyte models to study and predict drug-induced liver injury. The company describes it as Innovate UK-backed.
A research programme investigating human hepatocyte models to study and predict drug-induced liver injury. The company describes it as Innovate UK-backed; the reviewed sources do not establish an award identifier, amount, clinical predictive benchmark or regulatory qualification.
The company reports a former CSO role at bit.bio, group leadership at the UK Dementia Research Institute Cambridge and work on genome-wide CRISPR screens in neurons.
The company identifies him as founder of The Bioinformatics CRO and former VP Bioinformatics at bit.bio, with machine-learning and single-cell genomics experience.
The company reports previous communications leadership at Scorpion Therapeutics and business-development and scaling experience. This previous-employer history is not a CellCodex acquisition claim.
The company describes a life-sciences entrepreneurial background across academia, biotechnology and pharma.
Biographies and roles are company-attributed in the verified extraction.
